UBS AM
TXMD icon

UBS AM’s TherapeuticsMD TXMD Stock Holding History

UBS AM’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-7,236
Closed -$268K – 2901
2021
Q3 		$268K Hold
7,236
– – ﹤0.01% 2642
2021
Q2 		$431K Buy
7,236
+2,512
+53% +$152K ﹤0.01% 2580
2021
Q1 		$317K Buy
4,724
+2,353
+99% +$184K ﹤0.01% 2477
2020
Q4 		$143K Sell
2,371
-1,290
-35% -$88.1K ﹤0.01% 2526
2020
Q3 		$289K Sell
3,661
-980
-21% -$78.1K ﹤0.01% 2313
2020
Q2 		$290K Buy
4,641
+1,010
+28% +$58.8K ﹤0.01% 2292
2020
Q1 		$192K Sell
3,631
-487
-12% -$48.3K ﹤0.01% 2289
2019
Q4 		$498K Buy
4,118
+18
+0.4% +$2.59K ﹤0.01% 2237
2019
Q3 		$744K Buy
4,100
+1,221
+42% +$172K ﹤0.01% 2095
2019
Q2 		$374K Buy
2,879
+471
+20% +$84.4K ﹤0.01% 2331
2019
Q1 		$586K Buy
2,408
+199
+9% +$52.7K ﹤0.01% 2047
2018
Q4 		$421K Sell
2,209
-56
-2% -$13.7K ﹤0.01% 2064
2018
Q3 		$743K Buy
2,265
+33
+1% +$10.1K ﹤0.01% 1917
2018
Q2 		$697K Buy
2,232
+11
+0.5% +$3.36K ﹤0.01% 1951
2018
Q1 		$541K Buy
2,221
+256
+13% +$71.8K ﹤0.01% 2006
2017
Q4 		$594K Buy
1,965
+86
+5% +$23.9K ﹤0.01% 1916
2017
Q3 		$497K Buy
1,879
+199
+12% +$57.5K ﹤0.01% 1951
2017
Q2 		$443K Sell
1,680
-24
-1% -$6.01K ﹤0.01% 1917
2017
Q1 		$614K Buy
1,704
+215
+14% +$66.5K ﹤0.01% 1797
2016
Q4 		$430K Sell
1,489
-706
-32% -$219K ﹤0.01% 1847
2016
Q3 		$748K Buy
2,195
+76
+4% +$27.8K ﹤0.01% 1796
2016
Q2 		$902K Buy
2,119
+345
+19% +$142K ﹤0.01% 1703
2016
Q1 		$567K Sell
1,774
-201
-10% -$68.6K ﹤0.01% 1862
2015
Q4 		$1.02M Buy
1,975
+541
+38% +$200K ﹤0.01% 1738
2015
Q3 		$420K Buy
1,434
+480
+50% +$171K ﹤0.01% 2106
2015
Q2 		$375K Buy
+954
New +$337K ﹤0.01% 2227

Other funds holding TXMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

UBS AM's TXMD Position: Q4 2021 in Review

UBS AM sold out of TherapeuticsMD (TXMD) in Q4 2021, closing a stake of 7,236 shares — an estimated $268K sold.

UBS AM first reported a position in TXMD in Q2 2015 and held it in 26 quarters. The position peaked at $1.02M in Q4 2015. 131 funds tracked by Wall St. Rank hold TXMD as of Q4 2021.

  • UBS AM reported no remaining TherapeuticsMD position as of Q4 2021 after selling out during the quarter.
  • UBS AM sold 7,236 TherapeuticsMD shares in Q4 2021, an estimated $268K.
  • UBS AM first reported a position in TherapeuticsMD in Q2 2015 and held it in 26 quarters.
  • UBS AM's TherapeuticsMD position peaked at $1.02M in Q4 2015.
  • 131 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2021.

Based on UBS AM's 13F filing for Q4 2021, filed 14 Feb 2022.